Glide extends subcontract with Pfenex for solid dose formulation of rPA-based anthrax vaccine

The deal will see advancement of an alternative delivery method for Pfenex’s Px563L-mrPA, using Glide’s solid dose formulation technology.

The contract extension is the result of the National Institute of Allergy and Infectious Diseases (NIAID) exercising its first contract option under its existing contract with Pfenex.

Glide is focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics and it has a pipeline of products based on its solid dose injector, the Glide SDI.

Glide Technologies chief executive officer Dr Mark Carnegie-Brown said: "Following encouraging stability data with initial formulations we are pleased that NIAID continues to fund the progression of this program.

"We believe that a combination of Pfenex’s proprietary rPA-based anthrax vaccine and Glide’s novel formulations and delivery technology will address key issues with current products designed for a response to an anthrax bio-threat."

Glide SDI provides the potential of improved compliance in long-term therapy and improved immune responses to vaccines.

The company’s pipeline of solid dose formulations includes octreotide, parathyroid hormone and anthrax and influenza vaccines.